Scalper1 News
Analysts came to the defense of Canadian drug giant Valeant Pharmaceuticals (VRX) on Tuesday, after the stock sold off on word that some members of Congress were targeting it for its pricing policy. Valeant stock plunged 16.5% Monday, partly due to a larger drug sell-off but also because a group of congressional Democrats sent a letter to Rep. Jason Chaffetz, chair of the House Committee on Oversight and Government Reform, requesting a subpoena to Scalper1 News
Scalper1 News